The protocol at a glance
No dose is set. The human reports I could read used it by mouth and did not state the amounts.
| Item | What the sources show |
|---|---|
| Human dose | Not established |
| Route in human reports | By mouth |
| Amounts in human reports | Not stated in the papers I could read |
| Studied in | Cell cultures and small human reports |
Human reports come from a 2015 gerontology study and a 2021 review of KED. ClinicalTrials.gov lists no Vesugen trial (searched 5 Nov 2026).
Community notes report 500 mcg to 2 mg a day for 10 to 30 days. These are user reports, not trial data.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
Small human reports. No effect sizes are given in the abstracts:
Adv Gerontol 2015 (PMID 26390612); Bull Exp Biol Med 2021 (PMID 34173097).
Side effects
- The 2015 study found signs of more oxidant activity and fewer CD34+ blood stem cells, which its authors read as slower blood-cell production.
- No large safety trial exists.
How it works
Gene activity (lab)
In cell cultures KED changed genes for cell ageing and nerve-cell development.
Blood-vessel cells (lab)
In artery cell cultures it brought endothelin-1 back toward normal.
Sources
- Effect of synthetic peptides on aging in polymorbidity patients. Adv Gerontol 2015, PMID 26390612
- Peptide KED and neurogenesis in Alzheimer's disease. Bull Exp Biol Med 2021, PMID 34173097
- Vasoprotective peptide KED in atherosclerosis. Adv Gerontol 2016, PMID 28539025
- ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results